- Home
- DOW vs ILMN Comparison
DOW vs ILMN Comparison
Compare DOW & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOW
- ILMN
- Stock Information
- Founded
- DOW 1897
- ILMN 1998
- Country
- DOW United States
- ILMN United States
- Employees
- DOW N/A
- ILMN N/A
- Industry
- DOW Major Chemicals
- ILMN Medical Specialities
- Sector
- DOW Industrials
- ILMN Health Care
- Exchange
- DOW Nasdaq
- ILMN Nasdaq
- Market Cap
- DOW 16.5B
- ILMN 16.0B
- IPO Year
- DOW N/A
- ILMN 2000
- Fundamental
- Price
- DOW $25.09
- ILMN $101.80
- Analyst Decision
- DOW Hold
- ILMN Buy
- Analyst Count
- DOW 15
- ILMN 16
- Target Price
- DOW $30.53
- ILMN $125.31
- AVG Volume (30 Days)
- DOW 15.9M
- ILMN 1.9M
- Earning Date
- DOW 10-23-2025
- ILMN 07-31-2025
- Dividend Yield
- DOW 5.91%
- ILMN N/A
- EPS Growth
- DOW N/A
- ILMN N/A
- EPS
- DOW N/A
- ILMN 7.91
- Revenue
- DOW $41,819,000,000.00
- ILMN $4,284,000,000.00
- Revenue This Year
- DOW N/A
- ILMN N/A
- Revenue Next Year
- DOW $3.02
- ILMN $2.78
- P/E Ratio
- DOW N/A
- ILMN $12.87
- Revenue Growth
- DOW N/A
- ILMN N/A
- 52 Week Low
- DOW $20.40
- ILMN $68.70
- 52 Week High
- DOW $55.67
- ILMN $156.66
- Technical
- Relative Strength Index (RSI)
- DOW 54.56
- ILMN 55.53
- Support Level
- DOW $23.42
- ILMN $99.08
- Resistance Level
- DOW $24.47
- ILMN $102.80
- Average True Range (ATR)
- DOW 0.94
- ILMN 2.73
- MACD
- DOW 0.48
- ILMN 0.05
- Stochastic Oscillator
- DOW 96.90
- ILMN 83.33
About DOW Dow Inc.
Dow Chemical is a diversified global chemicals producer, formed in 2019 as a result of the DowDuPont merger and subsequent separations. The firm is a leading producer of several chemicals, including polyethylene, ethylene oxide, and silicone rubber. Its products have numerous applications in both consumer and industrial end markets.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.